FAS and prostate carcinoma: To accomplish this, Fas distribution in glioblastoma (U87), lung carcinoma (A549), liver carcinoma (HepG2), prostate cancer (PC3), and triple-negative breast cancer (SUM159) cells and in noncancerous human umbilical vein endothelial cells (HUVECs) was evaluated by immunofluorescence imaging.